Enveric Biosciences Inc. has announced new research detailing the first-ever isolation of a novel indolethylamine N-methyltransferase from the cane toad (Rhinella marina) and the successful development of a bioproduction platform for the isolation and pharmacological screening of novel indolethylamines.

Gilgamesh Pharmaceuticals Inc. has identified arylcyclo-hexylamine derivatives targeting N-methyl-D-aspartate receptor (NMDAR) and/or serotonin transporter (SERT) reported to be useful for the treatment of substance abuse and dependence, depression and mood and anxiety disorders.

Vicore Pharma Holding AB and its partner Alex Therapeutics AB reported positive results from the U.S. pilot phase of a study assessing the effects of digitally delivered cognitive behavioral therapy (CBT) in treating anxiety in patients with idiopathic pulmonary fibrosis (IPF). The four-week study in 10 patients found the digital therapeutic, called Almee, functioned properly, was safe and the user experience was favorable.

The potential for psychedelics to deliver long-lasting benefits for people with anxiety, depression, post-traumatic stress disorder and addiction is being put to the test in Australia, where new research and discovery centers are adding to a global enterprise of nearly 100 clinical trials underway in the space.

Vanderbilt University has patented metabotropic glutamate receptor subtype 2 (mGluR2) negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, obsessive-compulsive and autism spectrum disorders.